Insider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of Stock
TESARO Inc (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
TESARO Inc (NASDAQ TSRO) traded down $1.46 during mid-day trading on Tuesday, reaching $84.98. The company’s stock had a trading volume of 488,704 shares, compared to its average volume of 1,021,704. TESARO Inc has a 1 year low of $79.03 and a 1 year high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.69. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm had revenue of $142.77 million during the quarter, compared to the consensus estimate of $130.57 million. During the same quarter in the previous year, the business earned ($1.72) earnings per share. The firm’s quarterly revenue was up 740.3% compared to the same quarter last year. research analysts anticipate that TESARO Inc will post -8.16 earnings per share for the current year.
A number of equities analysts have recently weighed in on TSRO shares. Morgan Stanley reissued an “overweight” rating and issued a $165.00 price target (down from $181.00) on shares of TESARO in a report on Wednesday, November 8th. Cann reissued a “buy” rating and issued a $199.00 price target on shares of TESARO in a report on Friday, September 8th. Citigroup reissued a “buy” rating and issued a $216.00 price target on shares of TESARO in a report on Monday, September 11th. Zacks Investment Research lowered TESARO from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Finally, Wedbush reiterated an “outperform” rating and issued a $160.00 target price on shares of TESARO in a research note on Monday, September 11th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $159.39.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.